Cardiovascular diseases remain the leading cause of premature death in the developed world.
Acute Myocardial Infarction (AMI) is still the main cause of death in the industrial nations, with around three million people suffering from it every year. During the last decade, the treatment of patients with AMI has been revolutionised.
Time is an important factor for successful treatment
The most important factor for a successful treatment of an acute myocardial infarction is time to treatment. Reality shows, however, that from onset of symptoms until treatment a lot of precious time is wasted. Delays are caused by the patient's hesitance to call for help as well as by ambulance response and journey times and slow in-hospital procedures. Thrombolytic therapy has established itself as one of the most successful modern treatment options of an acute myocardial infarction. It is easy to apply, is available in all hospitals and is considered safe in view of the serious nature of the disease.
Products
Actilyse® (alteplase)
- Fibrinolytic treatment of acute myocardial infarction
- Thrombolytic treatment of acute massive pulmonary embolism
- Catheter clearance due to thrombotic occlusion
Actilyse® is also registered for the indication acute ischaemic stroke.
Metalyse® (tenecteplase)
- Fibrinolytic treatment in acute myocardial infarction
Disclaimer
We recognise that the Internet serves a global community. The pharmaceutical industry, however, is subject to country specific regulatory considerations, which affect the information we can provide on our products. In addition the registration status of pharmaceutical products may not be the same in different regions of the world and the approved product labels may also differ according to country specific requirements.
Therefore please check the registration details of this/these product(s) locally in order to get up-to-date information.
